Fosun Pharma Sets March 2026 Board Meeting to Approve 2025 Results and Dividend Plan

An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has scheduled a board meeting for 24 March 2026 to review and approve the audited financial results of the company and its subsidiaries for the year ended 31 December 2025. The board will also consider the recommendation of a final dividend and address other business matters, a step that will shape capital returns to shareholders and signal management’s view on the group’s earnings strength and financial outlook.

Investors will closely watch the outcome of the meeting, as the final results and any proposed dividend will provide clearer insight into the company’s operational performance and cash distribution policy after the 2025 financial year. The decisions taken could influence market confidence in Fosun Pharma’s balance between reinvestment in growth and rewarding shareholders, and may affect the stock’s valuation and appeal to income-focused investors.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare group listed in Hong Kong, operating across the pharmaceutical and medical sectors through a network of subsidiaries. The company is engaged in the research, development, manufacturing and distribution of medicines and healthcare products, serving domestic and international markets.

YTD Price Performance: 1.18%

Average Trading Volume: 3,611,276

Technical Sentiment Signal: Sell

Current Market Cap: HK$73.12B

Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.